In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Exicure (XCUR), with a price target of $7.00. The company’s shares closed last Wednesday at $2.05.
According to TipRanks.com, Nakae is a 4-star analyst with an average return of 7.0% and a 45.0% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Emergent Biosolutions, and NeuBase Therapeutics.
Currently, the analyst consensus on Exicure is a Moderate Buy with an average price target of $7.50.
See today’s analyst top recommended stocks >>
Based on Exicure’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $4.85 million and GAAP net loss of $4.31 million. In comparison, last year the company earned revenue of $434K and had a GAAP net loss of $5.22 million.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of XCUR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Exicure, Inc. engages in the provision of clinical stage biotechnology company. It offers 3-dimensional, spherical nucleic acid architecture unlocks the potential of nucleic acid therapeutics. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.
